CBD Reduced Binge Drinking in Mice Through an Unexpected Brain Mechanism

Acute CBD (7.5-120 mg/kg) dose-dependently reduced binge-like alcohol drinking and blood ethanol levels in mice. The effect was not due to sedation and was maintained across sub-chronic treatment. The well-known serotonin (5-HT1A) and PPARy receptor pathways were ruled out. Instead, the neuropeptide S receptor (NPSR) emerged as a potential mechanism.

Researchers used the drinking-in-the-dark mouse model of binge drinking. CBD was tested at multiple doses (7.5-120 mg/kg) in male and female mice. Behavioral pharmacology approaches tested CBD interaction with four receptor targets: 5-HT1A, PPARy, CXCR4, and NPSR.

Current medications for alcohol use disorder have limited efficacy. CBD's ability to reduce alcohol consumption through a novel receptor mechanism could open new treatment pathways.

If CBD reduces alcohol intake through NPSR rather than the previously suspected serotonin pathway, it suggests the mechanism is more novel than thought. This could lead to new drug development strategies targeting NPSR for alcohol use disorder.

Mouse model of binge drinking does not fully capture human alcohol use disorder. High doses used (up to 120 mg/kg) may not translate directly to human dosing. Single study identifying NPSR mechanism needs replication.